The Suzanne Somers Vanity Calamity, part 2: Logic? Who needs it.

Here is an example, from Knockout, of Suzanne Somers' attack on modern anti-cancer treatments such as chemotherapy. She writes,

  • "Cancer death rates dropped only 5 percent from 1950 to 2005. What other technology has performed so miserably over this fifty-five year period? In contrast, the death rate from heart disease dropped 64 percent in that time, and for flu and pneumonia it fell 58 percent."

I won't dispute these statistics, I don't know if they're accurate or not. Let's say they are. Somers commits the fallacy of Division: i.e. 'Cancer is a disease; therefore it should have achieved the same success rates, in the same time-frame, as other diseases.'

This is an invalid deductive argument. Heart disease is not cancer. The flu is not cancer. Beyond the most general categories, they have nothing in common. Certainly not at the biological level, where it matters. Yet this is what passes for convincing proof in Somers' mind. No wonder she seems to have no respect for the FDA's insistence that clinical studies of any drug or treatment submit to the most basic standards of the scientific method.

This is endemic of her book's wider argument; it devotes as much time to trash-talking conventional medicine as it does to gushing over supplements or therapies pitched by her 'experts', therapies that she herself often doesn't seem to understand.

I don’t think it would be too much to ask that she drop the efforts to disprove conventional treatments, and instead focus on proving the treatments she's promoting—not with lonely anecdotal 'evidence' or the even more absurd and worthless personal experience offered by Somers herself--but with randomized controlled, double-blind trials submitted for publication in respected medical journals. Such a measure would be a great leap forward in the advancement of alternative treatment modalities.

More to come on the latest book by this actress-turned-public-health-crisis ...

Link to Part 1
Link to Part 3
Link to Part 4
Link to Part 5

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap